Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
sales@dingminpharma.com
86-311-67591193
Model No.: DM 496775-62-3
Water: ≤0.5%
Purity: ≥99.0%
Residue On Ignition: ≤0.1%
Single Impurity: ≤0.5%
Appearance: Red To Brown Crystalline Powder
Packaging: Double PE Bag with Foil Bag or as required
Productivity: Stock available
Transportation: Ocean,Air,Courier
Place of Origin: Hebei,China
Supply Ability: As per order
Certificate: ISO9001
Port: Shanghai,Hangzhou,Shenzhen
Payment Type: L/C,T/T,D/P,Paypal
Incoterm: FOB,CFR,CIF,CPT,CIP
GOLDEN PRODUCT ELTROMBOPAG Intermediates CAS NO. 496775-62-3 :
Eltrombopag is a is an agonist of the c-mpl (TpoR) receptor used as treatment for thrombocytopenia.It has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts).
Product Name: Eltrombopag Olamine
Cas No.: 496775-62-3
Appearance: Red to Brown Crystalline Powder
Purity:99.0%+
Water：≤0.5%
Residue on ignition:≤0.1%
Heavy Metal:≤10ppm
Single impurity≤0.5%
Total impurities≤1.0%
Package&Shipping:
Package:Double PE Bag with Foil Bag or As required
Delivery time:Stock available
Port:Any port in China
Our productions of Eltrombopag Intermediates:
| Eltrombopag Project | Eltrombopag Olamine | 496775-62-3 |
| Eltrombopag | 496775-61-2 | |
| 3'-amino-2'-hydroxybiphenyl-3-carboxylic acid | 376592-93-7 | |
| 2'-hydroxy-3'-nitro-Biphenyl-3-carboxylic acid | 376591-95-6 | |
| 1-(3,4-dimethylphenyl)-3-methyl-3-pyrazolin-5-tone | 18048-64-1 | |
| 3,4-Dimethylphenylhydrazine hydrochloride | 86746-50-1 |
Description: IC50 Value: 0.27 uM (EC50 in murine BAF3 cells) Eltrombopag is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. Potential advantages of eltrombopag may include a sustained platelet response and a good tolerability profile. in vitro: Eltrombopag demonstrated a half maximal effective concentration (EC50) of 0.27 uM in murine BAF3 cells transfected with the luciferase reporter gene under direction of the STAT-activated IRF-1 promoter and human TpoR (BAF3/IRF-1/hTpoR). Eltrombopag stimulates the growth of TPO-dependent cell lines via JAK2 and STAT signaling pathways and stimulates isolated human CD34+ cells to become megakaryocytes and produce platelets. in vivo: Twelve weeks of antiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, and 75 mg of eltrombopag, respectively, and by 6% of patients in the placebo group. Eltrombopag was administered as once-daily oral capsules for 10 days at doses of 5, 10, 25, 30, 50, and 75 mg. The pharmacokinetics of eltrombopag was dose dependent and linear, and eltrombopag increased platelet counts in a dose-dependent manner. Toxicity: There were no apparent differences in the incidence or severity of adverse events in subjects receiving active or placebo study medication. Long-term treatment with eltrombopag was generally safe, well tolerated, and effective in maintaining platelet counts in the desired range. Clinical trial: Eltrombopag In Cord Blood Or Haploidentical Bone Marrow Transplantation. Phase 2
Product Categories : APIs And Intermediates > Eltrombopag Olamine Intermediates
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Contact Now